Literature DB >> 32483073

Efficacy and safety of a single-use dual blade goniotomy: 18-month results.

Susan M Wakil1, Faith Birnbaum, Daniel M Vu, Shan McBurney-Lin, Mohammed K ElMallah, Henry Tseng.   

Abstract

PURPOSE: To compare the 18-month efficacy and safety of Kahook Dual Blade goniotomy (KDB) in combination with cataract surgery (combined group) or as a standalone procedure (standalone group).
SETTING: Single surgeon practice.
DESIGN: Retrospective review study.
METHODS: A total of 116 eyes of 100 patients underwent KDB by a single well-experienced surgeon from May 2016 to 2018. A total of 93 eyes and 23 eyes were in the combined and standalone groups, respectively. Main outcome measures were reduction in intraocular pressure (IOP) and IOP-lowering medication and adverse events. Data were collected and analyzed using Welch t tests in R.
RESULTS: A total of 116 eyes of 100 patients were included in the analysis. Moderate or severe glaucoma was observed in 71% of eyes in the combined group compared with 83% in the standalone group. At baseline, mean IOP was 16.5 ± 5.0 mm Hg (n = 93) and 24.3 ± 9.1 mm Hg (n = 23) in the combined and standalone groups, respectively (P < .05). The IOP decreased in both groups at 12 months (14.1 ± 3.9 vs 16.9 ± 7.6, P = .24) and 18 months (14.4 ± 3.7 vs 16.7 ± 7.6, P = .5). There was a statistically significant difference in the number of drops between the combined and standalone groups at baseline (2.4 ± 1.2 vs 2.9 ± 1.0, P < .05) persisting at 12 months (1.3 ± 1.2 vs 2.6 ± 1.2, P < .05) and at 18 months (1.3 ± 1.2 vs 3.3 ± 1.2, P < .05). Complications included transient hyphemas (20 eyes [17%]) and IOP spike (20 eyes [17%]). Seven eyes required additional glaucoma surgery, 5 of which were in the standalone group.
CONCLUSIONS: KDB was an effective and safe procedure for different glaucoma disease severities, whether combined with cataract surgery or as a standalone surgery. It is an alternative to consider prior to pursuing more invasive glaucoma surgeries.

Entities:  

Mesh:

Year:  2020        PMID: 32483073     DOI: 10.1097/j.jcrs.0000000000000263

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  7 in total

1.  Excisional Goniotomy in Latino Patients with Open-Angle Glaucoma: Outcomes Through 24 Months.

Authors:  Matthew Porter; Arnulfo Garza; Mark Gallardo
Journal:  Clin Ophthalmol       Date:  2020-10-30

2.  Initial experience with phacoemulsification and goniotomy using the Kahook dual blade in advanced open-angle glaucoma: Six-month outcomes in Indian eyes.

Authors:  Rashmi Krishnamurthy; Sirisha Senthil; Nikhil Choudhari
Journal:  Indian J Ophthalmol       Date:  2021-09       Impact factor: 1.848

3.  Early Results of Irrigating Goniectomy With TrabEx+: A Novel Device for the Treatment of Open-angle Glaucoma.

Authors:  Daniel Gosling; Haoyu Wang; Graham Auger
Journal:  J Glaucoma       Date:  2022-04-01       Impact factor: 2.503

4.  Long-Term Outcomes of a Kahook Dual Blade Procedure Combined with Phacoemulsification in Japanese Patients with Open-Angle Glaucoma.

Authors:  Kentaro Iwasaki; Hiroshi Kakimoto; Yusuke Orii; Shogo Arimura; Yoshihiro Takamura; Masaru Inatani
Journal:  J Clin Med       Date:  2022-03-01       Impact factor: 4.241

Review 5.  A Review of Excisional Goniotomy Performed with the Kahook Dual Blade for Glaucoma Management.

Authors:  Syril Dorairaj; Nathan M Radcliffe; Davinder S Grover; Jacob W Brubaker; Blake K Williamson
Journal:  J Curr Glaucoma Pract       Date:  2022 Jan-Apr

6.  Predictive Factors of Outcomes in Kahook Dual Blade Excisional Goniotomy Combined with Phacoemulsification.

Authors:  Eli L Pratte; Junsang Cho; James R Landreneau; Matthew T Hirabayashi; Jella A An
Journal:  J Curr Glaucoma Pract       Date:  2022 Jan-Apr

7.  Outcomes of combined single-use dual blade goniotomy and cataract surgery.

Authors:  Sabine Baumgarten; Niklas Plange; Hla Myint Htoon; Tibor Lohmann; Andreas Videa; Antonis Koutsonas; Hannah Schellhase; David Kuerten; Peter Walter; Matthias Fuest
Journal:  Int Ophthalmol       Date:  2022-03-31       Impact factor: 2.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.